Results 41 to 50 of about 57,705 (278)

Multiple gene aberrations and breast cancer: lessons from super-responders. [PDF]

, 2015
BackgroundThe presence of multiple molecular aberrations in patients with breast cancer may correlate with worse outcomes.Case presentationsWe performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative, hormone ...
Atkins, Johnique T, Janku, Filip, Kurzrock, Razelle, Moulder, Stacy L, Stephens, Philip J, Wheler, Jennifer J, Yelensky, Roman   +6 more
core   +2 more sources

Skeletal Editing from Pyridine to Aniline via C‐Insertion and N‐Isomerization

ChemistryEurope, EarlyView.
A concise protocol is presented that converts pyridines into anilines by externalizing the original pyridine nitrogen at either the "ipso" or "ortho" position, which results in para or meta‐primary aniline products. A key carbene‐insertion step precedes nitrogen migration, preserving both ring size and overall structure.
Yun Luo, Jing Dai, Yongchang Wei, Chang Min   +3 more
wiley   +1 more source

A Systematic Review of Systematic Reviews on the Use of Aromatase Inhibitors for the Treatment of Endometriosis: The Evidence to Date

Drug Design, Development and Therapy, 2023
Panagiotis Peitsidis,1 Panagiotis Tsikouras,2 Antonio Simone Laganà,3 Alexandros Laios,4 Ioannis D Gkegkes,5 Christos Iavazzo6 1Department of Obstetrics and Gynecology Helena Venizelou Hospital, Athens, Greece; 2Department of Obstetrics and Gynecology ...
Peitsidis P, Tsikouras P, Laganà AS, Laios A, Gkegkes ID, Iavazzo C   +5 more
doaj  

Tactics for minimizing risk of increasing estradiol against the background of aromatase inhibitors in combination with gonadotropin releasing hormone agonists in adjuvant therapy for breast cancer in premenopausal patients. Pilot study results

Медицинский совет, 2018
Aromatase inhibitor (AI) combined with Gonadotropin-releasing hormone agonist (GnRH-a) have been recognized as an effective approach to adjuvant endocrinotherapy for breast cancer (BC) in premenopausal patients with adverse predictive factors.
I. B. Kononenko, A. V. Snegovoi, L. V. Manzyuk, E. I. Kovalenko, V. Yu. Selchuk   +4 more
doaj   +1 more source

Benzotriazole is antiestrogenic in vitro but not in vivo [PDF]

, 2007
Copyright © 2007 SETAC. This is the accepted version of the following article: Harris et al (2007), "Benzotriazole is antiestrogenic in vitro but not in vivo", Environmental Toxicology and Chemistry, 26(11), 2367–2372, which has been published in final ...
Brian, JV, Giger, W, Harris, CA, Routledge, EJ, Schaffner, C, Sumpter, JP   +5 more
core   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers [PDF]

, 2013
Introduction: We examined if a combination of proliferation markers and estrogen receptor (ER) activity could predict early versus late relapses in ER-positive breast cancer and inform the choice and length of adjuvant endocrine therapy.
Achim Rody, AJ Minn, Angelica Fasolo, B Haibe-Kains, B Thurlimann, Benjamin Haibe-Kains, C Bellera, C Davies, C Desmedt, C Kim, C Sotiriou, Catherine M Kelly, Christos Sotiriou, CJ van de Velde, D Sgroi, E Amir, G Bianchini, G Bianchini, G Tang, Giampaolo Bianchini, Gianluca Del Conte, H Jin, I Jatoi, JS Parker, KR Hess, KS Albain, Lajos Pusztai, Libero Santarpia, Luca Gianni, M Dowsett, M Filipits, M Schmidt, Marcus Schmidt, Milvia Zambetti, MJ Ellis, MJ van de Vijver, MM Regan, P Dubsky, R Simon, S Loi, S Loi, S Paik, Sven Becker, Takayuki Iwamoto, Thomas Karn, TO Nielsen, Uwe Holtrich, Volkmar Müller, W Fraser Symmans, WF Symmans, WR Miller, Y Wang, Y Zhang, Yuan Qi   +53 more
core   +1 more source

Annual Banned‐Substance Review 18th Edition—Analytical Approaches in Human Sports Drug Testing 2024/2025

Drug Testing and Analysis, EarlyView.
New insights into drug metabolism, distribution, elimination, and detection assays for drugs and methods of sports doping published between 2024 and 2025 are critically reviewed and evaluated in context with the Prohibited List 2025 as established by the World Anti‐Doping Agency.
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley   +1 more source

Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update

Breast Cancer: Targets and Therapy, 2011
Reva Schneider1, Ayman Barakat1, John Pippen1,2,3, Cynthia Osborne1,2,3 1Medical Oncology, Baylor-Sammons Cancer Center, 2Texas Oncology PA, 3US Oncology, Dallas, TX, USA Abstract: Estrogen and its metabolites play a significant role in the proliferation
Schneider RE, Barakat AY, Pippen JE, Osborne CR   +3 more
doaj  

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer [PDF]

, 2018
Background Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing ...
A Carracedo, A Subramanian, AH Evans, Allan Thornhill, Alshad S. Lalani, Aradhana Rani, C Trapnell, CK Osborne, CX Ma, Eugene Schuster, FL Chen, Francesca Avogadri-Connors, G Arpino, HJ Burstein, IE Smith, J Baselga, Joanna Nikitorowicz-Buniak, KE Bachman, KE O'Reilly, L Gandhi, LA Martin, LA Martin, Lesley-Ann Martin, LV Sequist, M Arnedos, M Dowsett, Mitch Dowsett, MT Weigel, N Patani, N Simigdala, NA O'Brien, Nikiana Simigdala, R Ribas, Ricardo Ribas, Richard E. Cutler, S Johnston, SC Drury, SN Mohd Nafi, SP Newman, Stephanie K. Guest, Stephen R. Johnston, Sunil Pancholi, T Nagashima, W Luo   +43 more
core   +6 more sources